下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Moderna Creates New Executive Committee Role Ahead of New Product Launches
Moderna在新产品发布前设立新的执行委员会角色

Accesswire ·  {{timeTz}}

Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion

胡安·安德烈斯被任命为总裁,战略伙伴关系和企业扩张

Jerh Collins Joins Moderna as Chief Technical Operations and Quality Officer to Succeed Juan Andres

杰赫·柯林斯加盟Moderna,担任首席技术运营和质量官,接替胡安·安德烈斯

CAMBRIDGE, MA / ACCESSWIRE / September 29, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the Company has expanded the Executive Committee to prepare for multiple upcoming new product launches. Effective January 1, 2023, Juan Andres will step into a new role as President, Strategic Partnerships and Enterprise Expansion, and will focus on building out the organization to support the growing pipeline. In this role, he will continue to serve on the Executive Committee and report to Mr. Bancel.

马萨诸塞州剑桥/ACCESSWIRE/2022年9月29日/亚洲网加利福尼亚州圣何塞12月23日电领先信使核糖核酸疗法和疫苗的生物技术公司Moderna今天宣布,该公司已经扩大了执行委员会,为即将推出的多个新产品做准备。自2023年1月1日起,胡安·安德烈斯将担任总裁的新职务,负责战略伙伴关系和企业扩张,并将专注于扩大组织规模,以支持不断增长的管道。在这一职位上,他将继续在执行委员会任职,并向班塞尔先生汇报工作。

Dr. Jerh Collins, Ph.D. will join the company as Chief Technical Operations and Quality Officer, succeeding Mr. Andres. Dr. Collins will join Moderna on October 3, 2022 and will assume the role of Chief Technical Operations and Quality Officer on January 1, 2023. Dr. Collins will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel.

Jerh Collins博士将加盟公司,接替安德烈斯先生,担任首席技术运营和质量官。柯林斯博士将于2022年10月3日加入Moderna,并将于2023年1月1日起担任首席技术运营和质量官。柯林斯博士将在Moderna执行委员会任职,并向斯特凡·班塞尔首席执行官汇报工作。

"Juan Andres has been an incredible partner in leading Moderna's manufacturing operations over the last several years, and he has played a crucial role in our COVID-19 vaccine production efforts, protecting and saving hundreds of millions of lives," said Moderna Chief Executive Officer Stéphane Bancel. "I am very pleased that Juan will apply his leadership and experience to allow Moderna to scale in its next phase of growth. Juan's continued leadership will be critical as we prepare for several upcoming new product launches."

Moderna首席执行官斯特凡·班塞尔表示:“在过去的几年里,胡安·安德烈斯一直是领导Moderna制造业务的令人难以置信的合作伙伴,他在我们的新冠肺炎疫苗生产努力中发挥了关键作用,保护和拯救了数亿人的生命。“我非常高兴,胡安将运用他的领导力和经验让Moderna在下一阶段的增长中扩大规模。在我们为即将到来的几款新产品发布做准备之际,胡安的持续领导将是至关重要的。”

"At the same time, we are incredibly excited to have Jerh Collins joining the Moderna team to succeed Juan as the company's next Chief Technical Operations and Quality Officer," Mr. Bancel continued. "Jerh joins Moderna with three decades of experience in global pharmaceutical manufacturing roles, including managing several manufacturing plants and as a Site Head. I'm confident that Jerh possesses the mindset and experience to expand our production footprint as we grow globally and internalize more of our production capabilities."

班塞尔接着说:“与此同时,我们非常高兴杰赫·柯林斯加入Moderna团队,接替胡安担任公司的下一任首席技术运营和质量官。”Jerh加入Moderna时拥有30年的全球制药制造经验,包括管理几家制造工厂和担任现场负责人。我相信Jerh拥有随着我们的全球增长和更多生产能力的内部化而扩大我们的生产足迹的心态和经验。

Dr. Collins joins Moderna from Novartis, where for the last nearly 30 years he had roles of increasing responsibility focused on pharmaceutical production and manufacturing, including roles serving as Head of Global Chemical Operations and Anti-Infectives and as Head of Global Chemical Operations. Dr. Collins received his Bachelor of Science in Chemistry and his Ph.D. in Organic Chemistry from University College Cork, Ireland. He also conducted post-doctoral cancer research at Arizona State University.

柯林斯博士从诺华公司加盟Moderna,在过去的近30年里,他在诺华公司担任的职务越来越多,主要关注药品生产和制造,包括担任全球化学运营和抗感染主管以及全球化学运营主管。柯林斯博士在爱尔兰科克大学获得化学理学学士学位和有机化学博士学位。他还在亚利桑那州立大学进行了博士后癌症研究。

"I'm incredibly excited to join Moderna, an organization that I have watched quickly scale technological and scientific breakthroughs for the benefit of people all around the world," said Dr. Collins. "It's a company that is redefining the future of medicine. I've also had the privilege of knowing and working with Juan for many years, and I am honored to continue his steady leadership of this team."

柯林斯博士说,“能够加入Moderna,我感到无比兴奋。我亲眼目睹了这个组织迅速推动科技突破,造福世界各地的人们。”这是一家正在重新定义医药未来的公司。我也有幸认识胡安并与他合作多年,我很荣幸能继续他对这个团队的稳定领导。

About Moderna

关于Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

在成立以来的10多年里,Moderna已经从一家推进信使核糖核酸领域计划的研究阶段公司,转变为一家拥有六种模式的多种临床疫苗和治疗产品组合的企业,在信使核糖核酸和脂质纳米颗粒制剂等领域拥有广泛的知识产权组合,以及一个能够大规模临床和商业生产的综合制造工厂。Moderna与国内外广泛的政府和商业合作伙伴保持着联盟关系。最近,Moderna的能力结合在一起,允许授权使用和批准一种最早和最有效的对抗新冠肺炎大流行的疫苗。

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit .

Moderna的信使核糖核酸平台建立在基础和应用信使核糖核酸科学、传递技术和制造的不断进步的基础上,并已使传染病、免疫肿瘤学、罕见疾病、心血管疾病和自身免疫性疾病的治疗和疫苗的开发成为可能。Moderna被评为生物制药行业最大雇主科学在过去的七年里。要了解更多信息,请访问。

Forward Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the appointment of Jerh Collins as the Company's Chief Technical Operations and Quality Officer; the transition of Juan Andres to the role of President, Strategic Partnerships and Enterprise Expansion; and the Company's preparations for upcoming new product launches. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, each filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.

本新闻稿包含经修订的“1995年私人证券诉讼改革法”所指的前瞻性陈述,包括有关:任命Jerh Collins为公司首席技术运营和质量官;胡安·安德烈斯过渡到总裁的角色,负责战略伙伴关系和企业扩张;以及公司为即将推出的新产品所做的准备。本新闻稿中的前瞻性声明既不是承诺,也不是保证,您不应过度依赖这些前瞻性声明,因为它们涉及已知和未知的风险、不确定性和其他因素,其中许多因素不是Moderna能够控制的,可能会导致实际结果与这些前瞻性声明中明示或暗示的内容大不相同。这些风险、不确定因素和其他因素包括在Moderna截至2021年12月31日的财政年度10-K表格年度报告和截至2022年3月31日的季度10-Q表格季度报告(分别提交给美国证券交易委员会(美国证券交易委员会))和Moderna提交给美国证券交易委员会的后续文件(可在美国证券交易委员会网站www.sec.gov上查阅)中在“风险因素”一栏下描述的其他风险和不确定因素。除非法律另有要求,否则在出现新信息、未来发展或其他情况时,Moderna不会对更新或修改本新闻稿中包含的任何前瞻性声明承担任何意图或责任。这些前瞻性陈述是基于Moderna目前的预期,仅代表截至本文发布之日。

Moderna Contacts

Moderna联系人

Media:
Chris Ridley
Vice President, Corporate Communications & Media
617-800-3651
Chris.Ridley@modernatx.com

媒体:
克里斯·里德利
总裁副主管,企业传播与媒体
617-800-3651
邮箱:Chris.Ridley@mediate natx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

投资者:
拉维纳·塔鲁克达尔
高级副总裁&投资者关系主管
617-209-5834
邮箱:Lavina.Talukdar@mediate natx.com

SOURCE: Moderna, Inc.

资料来源:Moderna公司


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。